Conducting clinical research studies with
SKILL, KNOWLEDGE and SAFETY.
Call to participate
860.443.4567

Posts Tagged ‘ HSDD ’

Decreased Zest for Sex?

Tuesday, February 6th, 2018

Lack of zing?  Low zest for sex?  Has your “mojo” left the dojo?

1 in 3 women are affected by low libido but many women are unwilling to discuss their lack of drive with their partners and their health care providers due to embarrassment and shame.  The lack of intimacy experienced by women and their partners can cause distress in a relationship.  Women who once enjoyed fulfilling relations now find themselves unable to connect intimately.  The love for their partner is there, but the desire and satisfaction has waned.

Decreased sexual desire, also known as Hypoactive Sexual Desire Disorder or HSDD, is a real medical condition.

Coastal Connecticut Research is currently involved in a clinical research study testing an investigational product for decreased desire.  There is no cost to participate in the study, no cost for the study product, and no cost for all study-related health care. Dr. Robert Spitz is the study gynecologist.  Study nurses are Diane Palmer RN and Kelley Sanok RN.

Women who would like to learn more about the decrease sexual desire study in New London are welcome to call (860) 443-4567.  All calls are confidential.

 

Decreased Desire Study Update

Monday, November 7th, 2016

Research volunteers truly do make a difference in this world.  It has been announced The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) has met the pre-specified co-primary efficacy endpoints in both Phase 3 clinical trials.

Palatin is developing bremelanotide as a subcutaneous, on-demand, as needed treatment for women who have not yet experienced menopause and have been diagnosed with HSDD.

“It was reported women using bremelanotide had clinically meaningful and statistically significant improvements in their desire and associated distress which are the defining clinical issues for an HSDD diagnosis,” said Carl Spana, Ph.D., President and CEO of Palatin.  He continued, “I am especially grateful to all of the women who volunteered to be a part of these studies.”

The CCRstudies team wishes to thank those women who came forward to participate in The Reconnect Study here in New London.  Dr. Robert Spitz served as the Primary Investigator of the study conducted at Coastal Connecticut Research, and Jessie Jellison Hatfield, LPN served as Study Coordinator.  We are truly grateful for all those who continually come forward to participate in research!

If you wish to learn more about becoming a volunteer for current or future studies are welcome to contact us today at (860)443-4567.